It has been revealed that glutamine treatment markedly raises SOD activity and reduces MDA content as well as increases Wnt3a protein levels in Alzheimer’s disease [31]. The gene discussed is WNT3A; the disease is early-onset autosomal dominant Alzheimer disease.